12/23
12:52 pm
regn
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]
Low
Report
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]
12/23
01:00 am
regn
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Low
Report
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
12/22
04:05 pm
regn
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
12/15
07:30 am
regn
Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]
Low
Report
Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]
12/13
10:37 am
regn
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow [Yahoo! Finance]
Low
Report
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow [Yahoo! Finance]
12/12
12:19 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an "equal weight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an "equal weight" rating on the stock.
12/11
02:58 pm
regn
Biohaven jumps on early-stage data for antibody drug conjugate combo [Seeking Alpha]
Low
Report
Biohaven jumps on early-stage data for antibody drug conjugate combo [Seeking Alpha]
12/11
06:23 am
regn
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
Low
Report
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
12/10
03:23 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $700.00 to $745.00. They now have an "equal weight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $700.00 to $745.00. They now have an "equal weight" rating on the stock.
12/7
04:30 pm
regn
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
Low
Report
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
12/6
04:23 pm
regn
Does Regeneron's Choppy 2025 Share Price Reflect Its Long Term Growth Potential? [Yahoo! Finance]
Low
Report
Does Regeneron's Choppy 2025 Share Price Reflect Its Long Term Growth Potential? [Yahoo! Finance]
12/4
09:44 pm
regn
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
12/4
02:03 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a "buy" rating on the stock.
12/4
09:04 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.
12/3
08:44 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
12/1
07:00 am
regn
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Medium
Report
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
12/1
07:00 am
regn
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Medium
Report
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
11/28
10:28 am
regn
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? [Yahoo! Finance]
Low
Report
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? [Yahoo! Finance]
11/28
03:37 am
regn
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients [Yahoo! Finance]
Low
Report
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients [Yahoo! Finance]
11/26
06:43 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
11/25
09:29 pm
regn
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
11/25
01:00 am
regn
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Medium
Report
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
11/24
11:00 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $798.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $798.00 price target on the stock.
11/24
10:12 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Scotiabank from $650.00 to $770.00. They now have a "sector perform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Scotiabank from $650.00 to $770.00. They now have a "sector perform" rating on the stock.
11/24
08:06 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $890.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $890.00 price target on the stock.